drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Allogeneic “universal” CAR T-cell therapy engineered to target glypican-3 (GPC3); single-dose infusion following lymphodepleting chemotherapy for advanced HCC and NSCLC.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Allogeneic T cells engineered with a chimeric antigen receptor targeting glypican-3 (GPC3). Upon binding GPC3 on tumor cells, the CAR activates T-cell effector functions, leading to cytotoxic killing via perforin/granzyme release and cytokine-mediated responses of GPC3-positive cancer cells.
drug_name
REVO-UWD-03
nct_id_drug_ref
NCT06653023